ArticleWorld journal of surgical oncology2026
Multi-omics analysis identifies BUB1B as a cell cycle-related driver of bladder cancer progression.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Bladder cancer (BC) is characterized by a high incidence and frequent recurrence. Despite efforts to improve survival and reduce mortality among BC patients, significant progress remains elusive. The role of the cell cycle in BC has been increasingly studied, and our analysis revealed that BC exhibits elevated expression of BUB1 mitotic checkpoint serine/threonine kinase B (BUB1B). However, the role of BUB1B in BC remains not fully understood. A Multi-omics analysis was performed by integrating BUB1B expression with clinical data, and the results indicated that the upregulation of BUB1B was associated with poor prognosis. Moreover, our study demonstrated that BUB1B promotes bladder cancer (BC) cell proliferation, migration, invasion, and tumorigenicity both in vitro and in vivo. Finally, subsequent analysis revealed a positive correlation of BUB1B expression with CDC25A and IFI6, and a negative correlation with CXCR6 and RGS4. In addition, our findings implicate the NF-κB signaling pathway in the function of BUB1B. These findings provided insights into the potential role of BUB1B as a therapeutic target for BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.